References
- Simon LV, Hashmi MF, Callahan AL. Neuroleptic malignant syndrome. StatPearls; 2022.
- Modi S, Dharaiya D, Schultz L, Varelas P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocrit Care 2016;24:97-103. https://doi.org/10.1007/s12028-015-0162-5
- Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000;85:129-35. https://doi.org/10.1093/bja/85.1.129
- Fukata S, Kawabata Y, Fujishiro K, et al. Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: a randomized, open-label prospective trial. Surg Today 2017;47:815-26. https://doi.org/10.1007/s00595-016-1441-2
- MacDonald K, Wilson MP, Minassian A, et al. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients. Gen Hosp Psychiatry 2010;32:443-5. https://doi.org/10.1016/j.genhosppsych.2010.04.005
- Drews JD, Christopher A, Evans DC. Neuroleptic malignant syndrome in the trauma intensive care unit: diagnosis and management of a rare disease in a challenging population. Int J Crit Illn Inj Sci 2017;7:119-21. https://doi.org/10.4103/IJCIIS.IJCIIS_100_16
- Farooq H, Mohammad T, Farooq A, Mohammad Q. Alcohol withdrawal mimicking neuroleptic malignant syndrome. Cureus 2019;11:e4697.
- Jesse S, Brathen G, Ferrara M, et al. Alcohol withdrawal syndrome: mechanisms, manifestations, and management. Acta Neurol Scand 2017;135:4-16. https://doi.org/10.1111/ane.12671
- Lappa A, Podesta M, Capelli O, et al. Successful treatment of a complicated case of neuroleptic malignant syndrome. Intensive Care Med 2002;28:976-7. https://doi.org/10.1007/s00134-002-1241-6
- Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist 2011;1:41-7. https://doi.org/10.1177/1941875210386491
- Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.
- Reulbach U, Dutsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007;11:R4.
- Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann Pharmacother 2008;42:1290-7. https://doi.org/10.1345/aph.1L066
- Janati AB, Alghasab N, Osman A. Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline. Case Rep Neurol Med 2012;2012:183252.
- Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989;50:18-25.